SBI Securities Co. Ltd. Raises Position in Pfizer Inc. $PFE

Posted by Brenda Bartman on May 6th, 2026

SBI Securities Co. Ltd. raised its stake in shares of Pfizer Inc. (NYSE:PFE – Free Report) by 8.0% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 550,371 shares of the biopharmaceutical company’s stock after purchasing an additional 40,920 shares during the period. SBI Securities Co. Ltd.’s holdings in Pfizer were worth $13,704,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Horizon Financial Services LLC raised its position in Pfizer by 174.8% during the fourth quarter. Horizon Financial Services LLC now owns 1,014 shares of the biopharmaceutical company’s stock valued at $25,000 after purchasing an additional 645 shares during the period. YANKCOM Partnership purchased a new stake in Pfizer during the fourth quarter valued at approximately $28,000. Grey Fox Wealth Advisors LLC bought a new stake in Pfizer in the third quarter worth about $29,000. Darwin Wealth Management LLC bought a new stake in Pfizer in the second quarter worth about $32,000. Finally, Torren Management LLC bought a new stake in Pfizer in the fourth quarter worth about $34,000. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Key Headlines Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

Positive Sentiment: Q1 results beat expectations: Pfizer reported $14.45B in revenue and $0.75 EPS, topping Street estimates as growth from recently launched and acquired products (notably Eliquis and cancer drugs) offset declines in COVID sales. Pfizer beats Q1 profit estimates on strong demand for blood thinner Eliquis (Reuters)
Positive Sentiment: Pipeline and M&A support longer-term growth: Management highlighted pipeline progress and the strategic Metsera acquisition (obesity) as key to offsetting legacy declines and to drive post‑2028 growth. Pfizer tops Wall Street estimates, reaffirms outlook as newer products show growth (CNBC)
Positive Sentiment: Legal and patent developments extend revenue visibility: A patent settlement around Vyndamax and recent favorable rulings (including COVID‑vaccine related wins) were cited as reshaping the company’s post‑2028 revenue outlook. Pfizer Says Vyndamax Drug Patent Settlement Reshapes Post-2028 Revenue View (Benzinga)
Positive Sentiment: New FDA approval: Pfizer (with Arvinas) won approval for VEPPANU, a first‑of‑its‑kind therapy for ESR1‑mutated advanced breast cancer, adding a near‑term commercial product. Pfizer, Arvinas Win FDA Nod For First-Of-Its-Kind Breast Cancer Therapy (Benzinga)
Neutral Sentiment: Guidance reiterated but with modest gaps vs. consensus: Pfizer reaffirmed FY‑2026 guidance (EPS $2.80–3.00; revenue $59.5B–62.5B), roughly in line but the EPS range is slightly conservative versus consensus, leaving limited upside in near‑term estimates. Pfizer Reports Strong First-Quarter Results And Reaffirms 2026 Guidance (BusinessWire)
Negative Sentiment: Higher R&D and expense pressure: Increased R&D spending weighed on profit, producing lower adjusted margins vs. the prior year and signaling near‑term profit pressure as the company invests in pipeline. Pfizer Revenue Rises But Profit Falls Amid Boosted R&D Spending (WSJ)
Negative Sentiment: Mixed market reaction and skepticism: Some analysts call the quarter “mild” — beats were offset by conservative guidance and margin pressures, so the report may not satisfy investors focused on near‑term sales acceleration. Why Pfizer’s ‘Mild’ First-Quarter Report Likely Won’t Satisfy Skeptics (Investors.com)

Pfizer Stock Performance

Pfizer stock opened at $26.42 on Wednesday. The company has a 50 day moving average price of $27.17 and a 200-day moving average price of $26.13. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.87 and a current ratio of 1.16. Pfizer Inc. has a fifty-two week low of $21.97 and a fifty-two week high of $28.75. The company has a market capitalization of $150.24 billion, a PE ratio of 19.43 and a beta of 0.35.

Pfizer (NYSE:PFE – Get Free Report) last posted its quarterly earnings results on Tuesday, May 5th. The biopharmaceutical company reported $0.75 earnings per share for the quarter, beating the consensus estimate of $0.72 by $0.03. Pfizer had a net margin of 12.42% and a return on equity of 20.48%. The firm had revenue of $14.45 billion during the quarter, compared to the consensus estimate of $13.84 billion. During the same quarter in the previous year, the firm posted $0.92 earnings per share. The company’s revenue was up 5.4% on a year-over-year basis. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. As a group, equities analysts forecast that Pfizer Inc. will post 2.99 earnings per share for the current year.

Pfizer Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, June 12th. Stockholders of record on Friday, May 8th will be paid a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a dividend yield of 6.5%. The ex-dividend date of this dividend is Friday, May 8th. Pfizer’s payout ratio is currently 126.47%.

Analyst Upgrades and Downgrades

Several analysts have issued reports on PFE shares. Weiss Ratings reissued a “hold (c-)” rating on shares of Pfizer in a research note on Thursday, January 22nd. Argus raised shares of Pfizer from a “hold” rating to a “buy” rating and set a $35.00 price objective for the company in a research note on Monday, March 2nd. Citigroup raised their price objective on shares of Pfizer from $26.00 to $27.00 and gave the stock a “neutral” rating in a research note on Wednesday, April 29th. Cantor Fitzgerald reissued a “neutral” rating and issued a $27.00 price objective on shares of Pfizer in a research note on Wednesday, February 4th. Finally, Guggenheim raised their price objective on shares of Pfizer from $35.00 to $36.00 and gave the stock a “buy” rating in a research note on Tuesday, March 24th. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, twelve have given a Hold rating and three have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $28.74.

Read Our Latest Report on PFE

About Pfizer

(Free Report)

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.